推进1型糖尿病管理:整合新型疗法、技术与辅助方法
该综述探讨1型糖尿病仍面临血糖异常、体重增加、血管并发症及心理困扰等问题,传统危险因素不能完全解释其心血管和肾脏疾病负担。胰岛素抵抗、炎症和内皮功能障碍可能参与其中,新型胰岛素类似物、非胰岛素辅助治疗及整合技术展现潜力,但需大型安慰剂对照试验验证联合治疗。
要点
- 1型糖尿病心血管和肾脏疾病负担重,传统危险因素解释不全。
- 胰岛素抵抗、炎症和内皮功能障碍可能独立于超重/肥胖起作用。
- 新型胰岛素类似物、非胰岛素辅助治疗及整合技术或可协同改善代谢。
核心结论
- 新型胰岛素类似物、非胰岛素辅助治疗与整合技术可能协同应对1型糖尿病独特的代谢功能障碍驱动因素。
研究设计与样本
- 综述,探讨技术与辅助治疗在1型糖尿病中的潜在协同作用。
主要发现
- 1型糖尿病患者仍面临血糖异常、体重增加、血管并发症、酮症酸中毒、严重低血糖和心理困扰。
- 心血管和肾脏疾病是1型糖尿病发病和死亡的主要原因,但传统危险因素不能完全解释超额负担。
- 新证据提示胰岛素抵抗、炎症和内皮功能障碍可能独立于超重/肥胖状态参与其中。
临床怎么用
- 可关注多激素系统、动态血糖和酮体监测、自动胰岛素滴定等创新技术。
- 可探索营养刺激激素疗法、胰岛素增敏剂和SGLT2抑制剂等作为辅助治疗。
局限性
- 需要大型安慰剂对照试验来推动联合治疗领域发展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In type 1 diabetes, a condition that necessitates lifelong exogenous insulin replacement, there is heavy reliance on technology-assisted insulin delivery and glucose monitoring. Yet, people living with type 1 diabetes still face dysglycemia, weight gain, vascular complications, ketoacidosis and severe hypoglycemia, and psychological distress. Cardiovascular and kidney disease remain the leading causes of morbidity and mortality, yet traditional risk factors (smoking, hypertension, hyperlipidemia, obesity, hyperglycemia) incompletely explain this excess burden. Emerging evidence highlights the role of insulin resistance, inflammation, and endothelial dysfunction exacerbated by current subcutaneous insulin therapies in type 1 diabetes, independent of overweight/obesity status. This has fueled interest in addressing metabolic challenges in type 1 diabetes through novel insulin analogs, adjunctive noninsulin therapies, and integrated technologies. Our review explores the potential synergy between technologies and adjunctive therapeutics to address unique physiologic drivers of metabolic dysfunction in type 1 diabetes. Innovations such as multihormonal systems, dynamic glucose and ketone monitoring, and automated insulin titration hold promise. However, leveraging emerging insights from nutrient-stimulated hormone-based therapies and other drug classes such as insulin-sensitizing agents and sodium-glucose cotransporter 2 inhibitors could pave the way for designing combination type 1 diabetes-specific therapies. Large, placebo-controlled trials are needed to progress the field toward use of combination therapies that reduce metabolic and vascular complications and ease patient burden in type 1 diabetes.
引用
- Snaith JR, Narongkiatikhun P, Bjornstad P, et al. Advancing Type 1 Diabetes Management: Integrating Novel Therapies, Technologies, and Adjunctive Approaches. Diabetes Care. 2026. PMID: 40880508. doi:10.2337/dci25-0015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。